There are 3163 resources available
257P - Spatial predictors of pathologic complete response to neoadjuvant chemotherapy using imaging mass cytometry in the IMMUcan TNBC cohort
Presenter: Andrea Joaquin Garcia
Session: Poster session 13
258P - Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC)
Presenter: Coralia Bueno Muiño
Session: Poster session 13
1954P - 5-methylthioadenosine phosphorylase (MTAP) loss in clinically advanced uveal melanoma (CAUM): A comprehensive genomic profiling (CGP) study
Presenter: Nimisha Srivastava
Session: Poster session 13
1955P - Glycan-programmed T cell immunity: Effective adoptive T cell transfer in a CRC preclinical model
Presenter: Yong Miao
Session: Poster session 13
1956P - Integrative analysis of 26848 human transcriptomes reveals cancer-defining transcriptional architecture at the isoform resolution
Presenter: Junghoon Shin
Session: Poster session 13
1957P - Integrative proteomic profiling in high-grade serous ovarian carcinoma: Unraveling biomarkers and therapeutic targets
Presenter: Ido Wolf
Session: Poster session 13
1958P - Influence of androgen deprivation therapy (ADT) on epithelial-mesenchymal transition (EMT) and cancer stem cell (CSC) features in prostate cancer (PCa)
Presenter: Marina Puchinskaya
Session: Poster session 13
1968P - Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)
Presenter: Jonathan Rosenberg
Session: Poster session 13
1969P - Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Presenter: Rohit Jain
Session: Poster session 13